175 related articles for article (PubMed ID: 34014777)
1. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience.
Bahçeci A; Paydaş S; Ak N; Ferhatoğlu F; Saip PM; Seydaoğlu G; Bilici M; Şimşek M; Tekin SB; Çalikuşu Z; Yavuz S; Şahin AB; Çubukçu E; Evrensel T; Değirmencioğlu S; Demiray AG; Yumuk PF; Alan Ö; Çikman Dİ; Demirelli FH; Köstek O; Gökyer A; Doğan M; Bal Ö; Çakar B; Gökmen E; Yamaç D; Korkmaz T; Aliyev A; Keskin Ö; Urvay S; Büyükşimşek M; Karadeniz C; Yildiz B; Çinkir HY; Demir H; Beypinar İ; Karaçin C; Eser K; Baykara M; Kiliçkap S; Okutur K; Bulut G; Alkan A; Arpaci E; Pilanci KN; Demir A; Işik D; Yildirim N
Cancer Invest; 2021; 39(6-7):473-481. PubMed ID: 34014777
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial.
Cortés J; Diéras V; Lorenzen S; Montemurro F; Riera-Knorrenschild J; Thuss-Patience P; Allegrini G; De Laurentiis M; Lohrisch C; Oravcová E; Perez-Garcia JM; Ricci F; Sakaeva D; Serpanchy R; Šufliarský J; Vidal M; Irahara N; Wohlfarth C; Aout M; Gelmon K
JAMA Oncol; 2020 Aug; 6(8):1203-1209. PubMed ID: 32584367
[TBL] [Abstract][Full Text] [Related]
3. Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer.
Kınıkoğlu O; Odabas H; Altıntaş YE; Yıldız A; Çakan B; Akdağ G; Yıldırım S; Bal H; Kaya T; Tünbekici S; Işık D; Başoğlu T; Yıldırım ME; Turan N
Medicina (Kaunas); 2024 Jun; 60(6):. PubMed ID: 38929568
[No Abstract] [Full Text] [Related]
4. Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients.
Tang E; Rowland A; McKinnon RA; Sorich MJ; Hopkins AM
Breast Cancer Res Treat; 2019 Nov; 178(2):473-477. PubMed ID: 31399933
[TBL] [Abstract][Full Text] [Related]
5. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
Al Rabadi LS; Cook MM; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
BMC Cancer; 2021 Oct; 21(1):1150. PubMed ID: 34706686
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment.
Watanuki R; Shimomura A; Yazaki S; Noda-Narita S; Sumiyoshi-Okuma H; Nishikawa T; Tanioka M; Sudo K; Shimoi T; Noguchi E; Yonemori K; Tamura K
Medicine (Baltimore); 2020 Sep; 99(38):e22331. PubMed ID: 32957402
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study.
Cil I; Kucukarda A; Atcı MM; Secmeler S; Paksoy N; Ferhatoglu F; Ak N; Ayhan M; Tataroglu Ozyukseler D; Onder AH; Avci O; Oyman A; Okten IN; Gulturk I; Akagunduz B; Basoglu T; Cakir E; Hacibekiroglu I; Ozcelik M; Aydiner A
Tumori; 2022 Feb; 108(1):19-25. PubMed ID: 34365852
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.
Jacot W; Pons E; Frenel JS; Guiu S; Levy C; Heudel PE; Bachelot T; D'Hondt V; Darlix A; Firmin N; Romieu G; Thezenas S; Dalenc F
Breast Cancer Res Treat; 2016 Jun; 157(2):307-318. PubMed ID: 27167986
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
Yokoe T; Kurozumi S; Nozawa K; Ozaki Y; Maeda T; Yazaki S; Onishi M; Fujimoto A; Nakayama S; Tsuboguchi Y; Iwasa T; Sakai H; Ogata M; Terada M; Nishimura M; Onoe T; Masuda J; Kurikawa M; Isaka H; Hagio K; Shimomura A; Okumura Y; Futamura M; Shimokawa M; Takano T
Breast Cancer; 2021 May; 28(3):581-591. PubMed ID: 33389616
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK
Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy.
Molinelli C; Parisi F; Razeti MG; Arecco L; Cosso M; Fregatti P; Del Mastro L; Poggio F; Lambertini M
Expert Rev Anticancer Ther; 2021 Mar; 21(3):241-250. PubMed ID: 33245671
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
Lu D; Li C; Riggs M; Polhamus D; French J; Agarwal P; Chen SC; Vadhavkar S; Patre M; Strasak A; Quartino A; Jin JY; Girish S
Cancer Chemother Pharmacol; 2019 Jul; 84(1):175-185. PubMed ID: 31102024
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population.
Noda-Narita S; Shimomura A; Kawachi A; Sumiyoshi-Okuma H; Sudo K; Shimoi T; Noguchi E; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
Breast Cancer; 2019 Jul; 26(4):492-498. PubMed ID: 30737616
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
15. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.
Montemurro F; Ellis P; Anton A; Wuerstlein R; Delaloge S; Bonneterre J; Quenel-Tueux N; Linn SC; Irahara N; Donica M; Lindegger N; Barrios CH
Eur J Cancer; 2019 Mar; 109():92-102. PubMed ID: 30708264
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
Chen SC; Quartino A; Polhamus D; Riggs M; French J; Wang X; Vadhavkar S; Smitt M; Hoersch S; Strasak A; Jin JY; Girish S; Li C
Br J Clin Pharmacol; 2017 Dec; 83(12):2767-2777. PubMed ID: 28733983
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917).
Nakayama T; Yoshinami T; Yasojima H; Kittaka N; Takahashi M; Ohtani S; Kim SJ; Kurakami H; Yamamoto N; Yamada T; Takata T; Masuda N
BMC Cancer; 2021 Jul; 21(1):795. PubMed ID: 34238257
[TBL] [Abstract][Full Text] [Related]
18. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer.
Tataroglu Ozyukseler D; Basak M; Ay S; Koseoglu A; Arıcı S; Oyman A; Sürmeli H; Turan M; Turan N; Odabaş H; E Yıldırım M
J Oncol Pharm Pract; 2021 Apr; 27(3):547-554. PubMed ID: 32423326
[TBL] [Abstract][Full Text] [Related]
20. A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients.
Due A; Berg T; Jensen MB; Yammeni S; Volmer L; Brems-Eskildsen AS; Andersen KK; Rana S; Knoop A; Kümler I
Acta Oncol; 2023 Feb; 62(2):126-133. PubMed ID: 36929759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
